A decision-support tool for the formulation of orally active, poorly soluble compounds

European Journal of Pharmaceutical Sciences

Volumn 32, Issue 2, 2007, Pages 128-139

  Branchu, Sébastien ^a   Rogueda, Philippe G ^a   Plumb, A Philip ^a   Cook, Walter G ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Artificial intelligence; Formulation; Nanoparticle; Physicochemical; Solid dispersion; Statistics

Indexed keywords

5 [5 (4,6 DIPHENYL 2 PYRIDYLOXY) 1,1 DIMETHYLPENTYL]TETRAZOLE; ABT 963; ALBENDAZOLE; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; AMPRENAVIR; APREPITANT; BMS 347070; CARBAMAZEPINE; CINNARIZINE; DANAZOL; FANTOFARONE; FENOFIBRATE; GI 197111X; GRISEOFULVIN; HALOFANTRINE; IBUPROFEN; INDOMETACIN; IRBESARTAN; ITRACONAZOLE; KETOPROFEN; LAB 687; LOPERAMIDE; MEBENDAZOLE; MEGESTROL ACETATE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NANOPARTICLE; NAPROXEN; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; PACLITAXEL; PG 301029; PIROXICAM; R 103757; RITONAVIR; SAQUINAVIR; SB 210661; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ARTICLE; DATA BASE; DECISION TREE; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; STATISTICS;

ARTIFICIAL INTELLIGENCE; AUTOMATIC DATA PROCESSING; CHEMISTRY, PHARMACEUTICAL; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; DECISION TREES; EXCIPIENTS; LEAST-SQUARES ANALYSIS; LIPIDS; NANOPARTICLES; REPRODUCIBILITY OF RESULTS; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 34548134498     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.06.005     Document Type: Article

References (36)

1. Aamodt A., and Plaza E. Case-based reasoning: foundational issues, methodological variations, and system approaches. Artif. Intell. Commun. 7 (1994) 39-59
2. Amidon G.L., Lennernäs H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
3. Berridge J.C. International Conference on Harmonisation Q8: Pharmaceutical Development. Pharmaceutical quality forum. November 2004 (2004)
4. Chen Y., Zhang G.G.Z., Neilly J., Marsh K., Mawhinney D., and Sanzgiri Y.D. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int. J. Pharm. 286 (2004) 69-80
5. Craw S., and Rowe R.C. Case-based reasoning for tablet formulations: a novel technology to re-use past formulations. Drug Delivery Companies Report (2002), Pharmaventures pp. 14-17
6. Damian F., Blaton N., Naesens L., Balzarini J., Kinget R., Augustijns P., and Van den Mooter G. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14 Eur. J. Pharm. Sci. 10 (2000) 311-322
7. European Federation for Pharmaceutical Sciences (EUFEPS) Conference, 2006. When poor solubility becomes an issue: from early stage to proof of principle, European Federation for Pharmaceutical Sciences, Verona, Italy, April 26-27, 2006.
8. Gough, P.H., 2004. ICH Q8 pharmaceutical development and Q9 quality risk management-an industry view.
9. Greenhalgh D.J., and Cook W.G. Relationship between drug and carrier solubility parameters and dissolution of solid dispersion systems. J. Pharm. Pharmacol 52 Suppl (2000) 299
10. Horspool K.R., and Lipinski C.A. Advancing new drug delivery concepts to gain the lead. Drug Deliv. Technol. 3 (2003) 35-46
11. Humberstone A.J., and Charman W.N. Lipid-based vehicles for the oral delivery of poorly water-soluble drugs. Adv. Drug Deliv. Rev. 25 (1997) 103-128
12. Hussain A.S. Process analytical technology: a first step in a journey towards the desired state. Process Anal. Technol. J. (2005) (article 18)
13. Kolodner J.L. An introduction to case-based reasoning. Artif. Intell. Rev. 6 (1992) 3-34
14. Kostewicz E.S., Wunderlich M., Brauns U., Becker R., Bock T., and Dressman J.B. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J. Pharm. Pharmacol. 56 (2004) 43-51
15. Lee J., Lee S.-J., Choi J.-Y., Yooa J.Y., and Ahnb C.-H. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur. J. Pharm. Sci. 24 (2005) 441-449
16. Lesko L.J., Rowland M., Peck C.C., Blaschke T.F., Breimer D., De Jong H.J., Grahnen A., Kuhlmann J.J., and Stewart B. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur. J. Pharm. Sci. 10 (2000) iv-xiv
17. Leuner C., and Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50 (2000) 47-60
18. Merisko-Liversidge E., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly water-soluble compounds. Eur. J. Pharm. Sci. 18 (2003) 113-120
19. Plumb A.P., Rowe R.C., York P., and Brown M. Optimisation of the predictive ability of artificial neural network (ANN) models: a comparison of three ANN programs and four classes of training algorithm. Eur. J. Pharm. Sci. 25 (2005) 395-405
20. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems. Eur. J. Pharm. Sci. 11 Suppl (2000) S93-S98
21. Pouton C.W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29 (2006) 278-287
22. PricewaterhouseCoopers, 1999. Pharma 2005-silicon rally: the race to e-R&D.
23. Quinlan J.R. Induction of decision trees. Mach. learn. 1 (1986) 81-106
24. Quinlan J.R. C4.5: Programs for Machine Learning (1993), Morgan Kaufmann Publishers, Inc., San Francisco, CA, USA
25. Ran Y., He Y., Yang G., Johnson J.L.H., and Yalkowsky S.H. Estimation of aqueous solubility of organic compounds by using the general solubility equation. Chemosphere 48 (2002) 487-509
26. Rinaki E., Dokoumetzidis A., and Macheras P. The mean dissolution time depends on the dose/solubility ratio. Pharm. Res. 20 (2003) 406-408
27. Rinaki E., Valsami G., and Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm. Res. 20 (2003) 1917-1925
28. Rowe R.C., and Roberts R.J. Intelligent Software for Product Formulation (1998), Taylor & Francis Ltd., London
29. Russell S.J., and Norvig P. Artificial Intelligence: A Modern Approach (2003), Prentice Hall
30. Serajuddin A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88 (1999) 1058-1066
31. Sun H. Predicting ADMET properties by projecting onto chemical space-benefits and pitfalls. Curr. Comput. Aided Drug Des. 1 (2005) 179-193
32. Tong W.-Q. Developability assessment supporting drug candidate selection. Integrated Drug Product Development Process (2006), University of Utah course, USA pp. 17-19
33. USA Food and Drug Administration (FDA), 2004. Innovation/ stagnation: challenge and opportunity on the critical path to new medical products, March 2004.
34. Veillard M. Decision making for standard versus non-standard development processes. EUFEPS Conference. Strasbourg, France, September 20-21, 2001 (2001)
35. Wassvik C.M., Holmén A.G., Bergström C.A., Zamora S., and Artursson I.P. Contribution of solid-state properties to the aqueous solubility of drugs. Eur. J. Pharm. Sci. 29 (2006) 294-305
36. Zhang G.G.Z., Law D., Schmitt E.A., and Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv. Drug. Deliv. Rev. 56 (2004) 371-390